Science

Yan Leyfman

Apr 3, 2025, 09:29

Yan Leyfman: Ammonia – A Hidden Obstacle in Cancer Immunotherapy

Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article by Joanna Domagala, et al. on LinkedIn:

“Ammonia: A Hidden Obstacle in Cancer Immunotherapy.

Immunotherapy has transformed cancer treatment, but the tumor microenvironment remains a major challenge. This study reveals that ammonia, a by-product of cancer cell metabolism, suppresses NK and T cell function, reducing the effectiveness of CAR-NK and CAR-T therapies.

Key Findings:

Ammonia weakens NK and T cells, impairing their ability to kill cancer cells.
It disrupts perforin maturation, a key weapon for immune cells.
By increasing pH in lysosomes, ammonia hampers immune response.

These insights highlight a new mechanism of tumor immune escape, paving the way for future strategies to overcome ammonia’s effects in cancer treatment.”

Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin.

Authors: Joanna Domagala, et al.

Yan Leyfman: Ammonia - A Hidden Obstacle in Cancer Immunotherapy

Ammonia cancer cancer immunotherapy cancer treatment CAR T therapies fight against cancer Global fight against cancer Joanna Domagala MedNews Week natural killer cells NK cell OncoDaily Oncology T cells Yan Leyfman

Val Kilmer Dies at 65: The Actor Who Fought Throat Cancer and Inspired Generations

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

Meet the New AACR Board of Directores for 2025-2028 Term